New clinical trial uses targeted cancer drug for lymphatic system disease

Epstein-Barr virus

Epstein-Barr virus (EBV)

Chronic infection with Epstein-Barr virus (EBV), a type of herpes virus, is associated with some lymphoproliferative disorders (LPDs) and non-Hodgkin lymphomas (NHLs). LPD is a disease in which cells of the lymphatic system grow excessively. NHL is a cancer that starts in white blood cells called lymphocytes, which are part of the immune system. Patients with EBV+ LPD and NHL express large amounts of a protein called PD-1 on their cell surfaces, which blocks the immune system from attacking cancer cells. Nivolumab is a targeted cancer drug that blocks the action of PD-1 and activates T cells to attack cancer cells without damaging normal cells, leading to fewer side effects. Mark Roschewski, M.D., of the Lymphoid Malignancies Branch is leading a study to determine if nivolumab is effective in treating certain diseases of the lymphatic system.

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Summary Posted: Tue, 05/01/2018